4,615,385 Shares1 CATALYST BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2020 • Catalyst Biosciences, Inc. • Pharmaceutical preparations • New York
Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,615,385 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 4,615,385 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 692,307 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
